CURRICULUM VITAE

Name: Paul F. Robbins

Phone Number: 301-402-2069

Email Address:

Education: June 1976 - B.S. (Biology) M.I.T., Cambridge,MA.

December 1982 - Ph.D. (Immunology),

Washington University, St. Louis, MO.

Chronology of Employment:

2008 to present - Staff Scientist, NIH,NCI, Surgery Branch

1996-2008 - Biologist, NIH, NCI, Surgery Branch

1994-1996 - Special Expert, NIH, NCI, Surgery Branch

1992-1994 - Senior Staff Fellow, NIH, NCI, Surgery Branch

1987-1992 - Senior Staff Fellow, NIH, NCI, DCBDC

1983-1987 - Postdoctoral fellow, Brandeis University

Membership in Scientific

Societies:

American Association of Immunologists

International Society for the Biological Therapy of Cancer

American Association for Cancer Research

Honors and Scientific Recognition:

Reviewer for Scientific Journals

Section Editor, The Journal of Immunology

Ad hoc reviewer for NIST Advanced Technology Program, Cancer Research, Cellular Immunology, and Journal of Clinical Oncology

Invited lectures

“Antigens recognized by melanoma-reactive T cells and the development of cancer immunotherapies”

Cancer Immunotherapy Marseille, France April 2, 1997

“Tumor Antigen Discovery”

Seminar at the Istituto Nazionale Tumori, Milan, Italy April 5, 1997

“Nature of Antigens recognized by melanoma reactive T cells”

American Association of Clinical Oncology Denver, Colorado May 17, 1997

“Antigen Discovery in Melanoma”

Melanoma at the Millenium Phoenix, Arizona February 19, 2000

“Anti-tumor immunity and immune escape in melanoma”

11th International Congress of Immunology Stockholm, Sweden July 27, 2001

“Analysis of T cell persistence in melanoma patients receiving adoptive immunotherapy” International Meeting on Cancer Vaccines, Istituto Superiore di Sanità Rome, Italy April 20, 2004

“Factors that influence response to adoptive cancer immunotherapy” International Society for the Biological Therapy of Cancer Alexandria, Virginia, November 11, 2005.

“Factors that influence response to adoptive immunotherapy” International Meeting on Cancer Vaccines, Istituto Superiore di Sanita Rome, Italy May 25, 2006.

“Current perspective on cancer adoptive immunotherapy” Italian Melanoma Intergroup 12th Annual Meeting, Bari, Italy December 2, 2006.

“Development of effective T cell adoptive cancer immunotherapies”, International Symposium on Immunotherpy and Immunodeficiency, Heidelberg, Germany, November 20, 2009.

“Tumor regression in patients with metastatic synovial sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1” AACR Annual Meeting, Washington D.C., April 19, 2010.

“Adoptive Immunotherapy of Synovial Cell Sarcoma Targeting Cancer/Testis Antigens”, ASCO Annual Meeting, Chicago, IL, June 4, 2011.

Collaborations:

Extramural

Mechanism involved with the processing of spliced T cell epitopes

Collaborators: Dr. Benoit J. Van den Eynde and Dr. Nathalie Vigneron, Tumor immunology and antigen processing group Ludwig Institute for Cancer Research, Brussels Branch

Intramural

Identification of mutated candidate peptide T cell epitopes by total exomic sequencing of human melanoma DNA

Collaborator: Dr. Yardena Samuels, National Human Genome Research Institute, NIH, Bethesda, MD.

Clinical Trial Participation:

Characterization of recombinant gp100 protein

Clinical Center Protocol Number: 03-C-0299A

Phase II study of metastatic cancer that expresses NY-ESO-1 using lymphodepleting conditioning followed by infusion of anti-NY-ESO-1-gene engineered lymphocytes

Clinical Center Protocol Number: 08-C-0121

Phase I/II Study of Metastatic Cancer that Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Gene Engineered Lymphocytes Cotransduced with Genes Encoding IL-12 and Anti-NY ESO-1 TCR

Clinical Center Protocol Number: 12-C-0006

PUBLICATIONS

Original Peer-reviewed manuscripts

1. Wilner, G.D., Thomas, D.W., Nossel, H.L., Robbins, P.F., and Mudd, M.S.: Immunochemical analysis of rabbit antihuman fibrinopeptide B antibodies. Biochemistry 18:5078-5082, 1978.

2. Kapp, J.A., Strayer, D.S., Robbins, P.F., and Perlmutter, R.M. Insulin-specific murine antibodies of limited heterogeneity. I. Genetic control of spectrotypes. J. Immunol. 123:109-114, 1979.

3. Robbins, P.F., Thomas, J.W., Jensen, P.E., and Kapp, J.A.: Insulin-specific tolerance induction. I. Abrogation of helper T cell activity is controlled by H-2-linked Ir genes. J. Immunol. 132:43-49, 1984.

4. Kapp, J.A., Jensen, P.E., Robbins, P.F., and Fritschle, C.: Insulin-specific tolerance induction. II. Tolerant helper T cells can be rescued by insulin complexed to Brucella abortus. J. Immunol. 133:2888-2891, 1984.

5. Robbins, P.F., Rosen, E.M., Haba, S., and Nisonoff, A.: Relationship of VH and VL genes encoding three idiotypic families of anti-p-azobenzenearsonate antibodies. Proc.Natl. Acad. Sci. U.S.A. 83:1050-1054, 1986.

6. Robbins, P.F., and Nisonoff, A.: Characteristics of two idiotypic subfamilies of anti-p-azobenzenearsonate antibodies. J. Immunol. 139:3868-3877, 1987.

7. Durdik, J., Gerstein, R.M., Rath, S., Robbins, P.F., Nisonoff, A., and Selsing, E.: Isotype switching by a microinjected mu immunoglobulin heavy chain gene in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 86:2346-2350, 1989.

8. Guadagni, F., Witt, P.L., Robbins, P.F., Schlom, J., and Greiner, J.W.: Regulation of Carcinoembryonic antigen expression in different human colorectal tumor cells by interferon-g. Cancer Res. 50:6248-6255, 1990.

9. Robbins, J., Robbins, P.F., Kozak, C.A., and Callahan, R.: The mouse biliary glycoprotein gene (Bgp): Partial nucleotide sequence, expression, and chromosomal assignment. Genomics 10:583-587, 1991.

10. Robbins, P.F., Kantor, J.A., Salgaller, M., Hand, P.H., Fernsten, P.D., and Schlom, J.: Transduction and expression of the human carcinoembryonic antigen (CEA) gene in a murine colon carcinoma cell line. Cancer Res. 51:3657-3662, 1991.

11. Robbins, P.F., Eggensperger, D., Chen-Feng, Q., and Schlom, J.: Definition of the expression of the human carcinoembryonic antigen and non-specific crossreacting antigen in human breast and lung carcinomas. Int. J. Cancer 53:892-897, 1993.

12. Horan Hand, P., Robbins, P.F., Salgaller, M., Poole, D.J., and Schlom, J.: Evaluation of human CEA-transduced and non-transduced murine tumors as potential targets for anti-CEA therapies. Cancer Immunol. Immunother. 36:65-75, 1993.

13. Salgaller, M., Bei, R., Schlom, J., Poole, D.J., and Robbins, P.F.: Baculovirus recombinants expressing the human carcinoembryonic antigen gene. Cancer Res. 53:2154-2161, 1993.

14. Kawakami, Y., Eliyahu, S., Delgado, C.H., Robbins, P.F., Rivoltini, L., Topalian, S.L., Miki, T., and S. Rosenberg.: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating tumor. Proc. Natl. Acad. Sci. U.S.A. 91:3515-3519, 1994.

15. Kawakami, Y., Eliyahu, S., Delgado, C.H., Robbins, P.F., Sakaguchi, K., Appella, E., Yanelli, J.R., Adema, G.J., Miki, T., and Rosenberg, S.A.: Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. U.S.A. 91:6458-6462, 1994.

16. Kawakami, Y., Eliyahu, S., Sakaguchi, K., Robbins, P.F., Rivoltini, L., Yanelli, J.B., Appella, E., and Rosenberg, S.A.: Identification of the immunodominant peptides of MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:347-352, 1994.

17. Robbins, P.F., El-Gamil, M., Kawakami, Y., Stevens, E., Yannelli, J.R., and Rosenberg, S.A.: Recognition of tyrosinase by tumor infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res. 54:3124-3126, 1994.

18. Topalian, S.L., Rivoltini, L., Mancini, M., Markus, N.R., Robbins, P.F., Kawakami, Y., and Rosenberg, S.A.: Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. Natl. Acad. Sci. U.S.A. 91:9461-9465, 1994.

19. Wang, Rong-Fu, Robbins, P.F., Kawakami, Y., Kang, X.-Q., and S.A. Rosenberg.: Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J. Exp. Med. 181:799-804, 1995.

20. Kawakami, Y., Eliyahu, S., Jennings, C., Sakaguchi, K., Kang, X., Southwood, S., Robbins, P.F., Sette, A., Appella, E., and Rosenberg, S.A.: Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor infiltrating T-lymphocytes associated with in vivo tumor regression. J. Immunol. 154:3961-3968, 1995.

21. Stevens, E.J., Jacknin, L., Robbins, P.F., Kawakami, Y., El Gamil, M., Rosenberg, S.A., and Yannelli, J.R.: Generation of tumor-specific cytotoxic T lymphocytes from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. J. Immunol. 154:762-771, 1995.

22. Rivoltini, L, Kawakami, Y., Sakaguchi, K., Southwood, S., Sette, A., Robbins, P.F., Marincola, F. M., Salgaller, M.L., Yannelli, J.R., Appella, E.,and S.A. Rosenberg: Induction of tumor reactive CTL from peripheral blood and tumor infiltrating lymphocytes of melanoma patients by in vitro stimulation with the human melanoma antigen MART-1 peptide. J. Immunol. 154:2257-2265, 1995.

23. Robbins, P.F., El-Gamil, Mona, Li, Yong, Topalian, S.L, Rivoltini, L., Sakaguchi, K, Appella, E., Kawakami, Y., and Rosenberg, S.A.: Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24 restricted tumor infiltrating lymphocytes. J. Immunol. 154:5944-5950, 1995.

24. Kang, X., Kawakami, Y., Sakaguchi, K., El-Gamil, M., Wang, R., Yannelli, J., Appella, E., Rosenberg, S.A., and Robbins, P.F.: Identification of a tyrosinase epitope recognized by HLA-A24 restricted tumor-infiltrating lymphocytes. J. Immunol. 155:1343-1348, 1995.

25. Yannelli, J. R., McConnell, S., Parker, L., Nishimura, M., Robbins, P., Yang, J., El-Gamil, M., Kawakami, Y.: Melanoma tumor-infiltrating lymphocytes derived from four distinct anatomic sites obtained from a single patient: comparison of functional reactivity and melanoma antigen recognition. J. Immunother. 18:263-271, 1995.

26. Robbins, P.F., El-Gamil, M, Li, Y.F., Kawakami, Y., Loftus, D., Appella, E., and Rosenberg, S. A.: A mutated b-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183:1185-1192, 1996.

27. Wang, W.-F., Parkhurst, M., Kawakami, Y., Robbins, P.F., and Rosenberg, S.A.: Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J. Exp. Med. 183:1131-1140, 1996.

28. Topalian, S.L., Gonzalex, M.I., Parkhurst, M., Li, Y.F., Southwood, S., Sette, A., Rosenberg, S.A., and Robbins, P.F.: Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J. Exp. Med. 183:1965-1971, 1996.

29. Parkhurst, M.R., Salgaller, M.L, Southwood, S., Robbins, P.F., Sette, A., Rosenberg,S.A., and Kawakami, Y.: Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol. 157:2539-2548, 1996.

30. Kawakami, Y., and Robbins, P.F.: Human tumor antigens recognized by T cells. Current Opinion in Immunol. 8:628-636, 1996.

31. Kawakami, Y., Robbins, P. F., and Rosenberg, S. A.: Human melanoma antigens recognized by T lymphocytes. Keio J. Med. 45:100-108, 1996.

32. Kang, X., Robbins, P. F., Fitzgerald, E. B., Wang, R., Rosenberg, S. A., and Kawakami, Y.: Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope-major histocompatibility complex class I fusion proteins. Cancer Res. 57:202-205, 1997.

33. Kawakami, Y., Battles, J.K., Kobayashi, T., Ennis, W., Wang, Xiang, Tupesis, J.P., Marincola, F.M., Robbins, P.F., Hearing, V.J., Gonda, M.A., and Rosenberg, S.A.: Production of

recombinant MART-1 proteins and specific anti-MART-1 polyclonal and monoclonal

antibodies: Use in the characterization of the human melanoma antigen MART-1 J. Immunol. Methods. 202:13-21, 1997.

34. Bloom, M.B., Perry-Lalley, D., Robbins, P.F. Li, Y., El-Gamil, M., Rosenberg, S.A., Yang,

J.C.: Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 185:453-459, 1997.

35. Rubenfeld, B., Robbins, P., El-Gamil, M., Albert, I., Porfiri, E., and Polakis, P.:

Stabilization of b-catenin by genetic defects in melanoma cell lines. Science 275:1790-1792, 1997.

36. Robbins, P.F., El-Gamil, M., Li, Y.F., Fitzgerald, E.F., Kawakami, Y., and Rosenberg, S.A.:

The intronic region of an incompletely-spliced gp100 gene transcript encodes an epitope recognized by melanoma reactive tumor infiltrating lymphocytes. J. Immunol.159:303-308, 1997.

37. Kawakami, Y., Robbins, P.F., Wang, R. F., Parkhurst, M., Kang, X., and Rosenberg, S.A.: The use of melanosomal proteins in the immunotherapy of melanoma. J. Immunother. 21:237-246, 1998.

38. Wang, R.-F., Wang, X., Jonhston, S.L., Zeng, G., Robbins, P.F., and Rosenberg, S.A.:

Development of a retrovirus-based complementary DNA expression system for the cloning of tumor antigens. Cancer Res. 58:3519-3525, 1998.

39. Kawakami, Y., Robbins, P.F., Wang, X., Tupesis, J., Parkhurst, M., Kang, X., Sakaguchi, K,

Appella, E., and Rosenberg, S.A.: Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and –A3 alleles. J. Immunol. 161:6985-6992, 1998.

40. Clay, T.M., Custer, M.C., McKee, M., Parkhurst, M., Robbins, P.F., Kerstann, K., Wunderlich, J., Rosenberg, S.A., and Nishimura, M.I.: Changes in the fine specificity of gp100(209-217) reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. J. Immunol. 162:1749-1755, 1998.

41. Irvine, K.R., Parkhurst, M.R., Shulman, E.P., Tupesis, J.P., Custer, M., Touloukian, C.E., Robbins, P.F., Yafal, A.G., Greenhalgh, P., Sutmuller, R.P.M., Offringa, R., Rosenberg, S.A., and Restifo, N.R.: Recombinant virus vaccination against “self” antigens using anchor-fixed immunogens. Can. Res. 59:2536-2540, 1999.

42. Nishimura, M. I., Avichezer, D., Custer, M. C., Lee, C. S., Chen, C., Parkhurst, M. R., Diamond, R. A., Robbins, P. F., Schwartzentruber, D. J., and Rosenberg, S. A.: MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte. Can. Res. 59:6230-6238, 1999.

43. Bonvini, P, Hwang, S.G., El-Gamil, M., Robbins, P., Neckers, L., and Trepel, J.: Melanoma cell lines contain a proteasome-sensitive, nuclear cytoskeleton-associated pool of beta-catenin. Ann. N.Y. Acad. Sci. 886:208-211, 1999.

44. Kawakami, Y., Dang, N., Wang, X., Tupesis, J., Robbins, P.F., Wang, R.-F., Wunderlich, J., Yannelli, J. R., and Rosenberg, S.A.: Recognition of shared melanoma anitgens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. J. Immunother. 23:17-27, 2000.

45. Somasundaram, R., Robbins, P., Moonka, D., Loh, E., Marincola, F., Patel, A., Guerry, D.P, and Herlyn, D.: CD4+, HLA class I-restricted, cytolytic T-lymphocyte clone against primary malignant melanoma cells. Int. J. Can. 85:253-259, 2000.

46. Panelli, M. C., Bettinotti, M. P., Lally, K., Ohnmacht, G. A., Li, Y., Robbins, P., Riker, A., Rosenberg, S. A., and Marincola, F. M.: A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12. J. Immunol. 164:4382-4392, 2000.

47. Touloukian, C. E., Leitner, W. W., Topalian, S. L., Li, Y. F., Robbins, P. F., Rosenberg, S. A., and Restifo, N. P.: Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice. J. Immunol. 164:3535-3542, 2000.

48. Bonvini, P., Hwang, S., El-Gamil, M., Robbins, P., Kim., J., Trepel, J., and Neckers, L.: Nuclear beta-catenin displays GSK-3beta- and APC-independent proteasome sensitivity in melanoma cells. Biochem., Biophys, Acta. 1495:308-318, 2000.

49. Touloukian, C. E., Leitner, W. W., Robbins, P. F. , Rosenberg, S. A., and Restifo, N. P.: Mining the Melanosome for Tumor Vaccine Targets: P.polypeptide Is a Novel Tumor-associated Antigen. Cancer Res. 61:8100-8104, 2001.

50. Zeng, G., Wang, X., Robbins, P. F., Rosenberg, S. A., and Wang, R. F.: CD4(+) T cell recognition of MHC class II-restricted epitopes from NY- ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO- 1 antibody production. Proc Natl Acad Sci U S A. 98: 3964-3969, 2001.

51. Harada, M., Y.F. Li, M. El-Gamil, S.A. Rosenberg, and P.F. Robbins.: Use of an in vitro immunoselected tumor cell line to identify shared melanoma antigens recognized by HLA-A*0201-restricted T cells. Cancer Res. 61:1089-1094, 2001.

52. Harada, M., Li, Y.F., El-Gamil, M., Ohnmacht, G.A., Rosenberg, S.A., and Robbins, P.F.: Melanoma reactive CD8+ T cells recognize a novel tumor antigen expressed in a wide variety of tumor types. J. Immunother. 323-333, 2001.